GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Kite Pharma Inc (NAS:KITE) » Definitions » Beneish M-Score

Kite Pharma (Kite Pharma) Beneish M-Score : 0.00 (As of May. 04, 2024)


View and export this data going back to 2014. Start your Free Trial

What is Kite Pharma Beneish M-Score?

The zones of discrimination for M-Score is as such:

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator.
An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

The historical rank and industry rank for Kite Pharma's Beneish M-Score or its related term are showing as below:

During the past 5 years, the highest Beneish M-Score of Kite Pharma was 0.00. The lowest was 0.00. And the median was 0.00.


Kite Pharma Beneish M-Score Historical Data

The historical data trend for Kite Pharma's Beneish M-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Kite Pharma Beneish M-Score Chart

Kite Pharma Annual Data
Trend Dec12 Dec13 Dec14 Dec15 Dec16
Beneish M-Score
- - - - -3.39

Kite Pharma Quarterly Data
Dec12 Mar13 Jun13 Sep13 Dec13 Mar14 Jun14 Sep14 Dec14 Mar15 Jun15 Sep15 Dec15 Mar16 Jun16 Sep16 Dec16 Mar17 Jun17
Beneish M-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -1.57 -2.66 -3.39 -3.30 -3.26

Competitive Comparison of Kite Pharma's Beneish M-Score

For the Biotechnology subindustry, Kite Pharma's Beneish M-Score, along with its competitors' market caps and Beneish M-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Kite Pharma's Beneish M-Score Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Kite Pharma's Beneish M-Score distribution charts can be found below:

* The bar in red indicates where Kite Pharma's Beneish M-Score falls into.



Kite Pharma Beneish M-Score Calculation

The M-score was created by Professor Messod Beneish. Instead of measuring the bankruptcy risk (Altman Z-Score) or business trend (Piotroski F-Score), M-score can be used to detect the risk of earnings manipulation. This is the original research paper on M-score.

The M-Score Variables:

The M-score of Kite Pharma for today is based on a combination of the following eight different indices:

M=-4.84+0.92 * DSRI+0.528 * GMI+0.404 * AQI+0.892 * SGI+0.115 * DEPI
=-4.84+0.92 * 1+0.528 * 1+0.404 * 0.8026+0.892 * 1.6152+0.115 * 0.7519
-0.172 * SGAI+4.679 * TATA-0.327 * LVGI
-0.172 * 1.2548+4.679 * -0.22102-0.327 * 1.4427
=-3.26

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Jun17) TTM:Last Year (Jun16) TTM:
Total Receivables was $0.00 Mil.
Revenue was 10.052 + 9.836 + 4.907 + 7.341 = $32.14 Mil.
Gross Profit was 10.052 + 9.836 + 4.907 + 7.341 = $32.14 Mil.
Total Current Assets was $798.28 Mil.
Total Assets was $907.11 Mil.
Property, Plant and Equipment(Net PPE) was $49.72 Mil.
Depreciation, Depletion and Amortization(DDA) was $12.69 Mil.
Selling, General, & Admin. Expense(SGA) was $134.35 Mil.
Total Current Liabilities was $88.56 Mil.
Long-Term Debt & Capital Lease Obligation was $0.00 Mil.
Net Income was -109.822 + -90.399 + -84.935 + -73.946 = $-359.10 Mil.
Non Operating Income was -2.91 + 0.428 + -0.294 + -0.031 = $-2.81 Mil.
Cash Flow from Operations was -34.877 + -17.807 + -53.911 + -49.21 = $-155.81 Mil.
Total Receivables was $0.00 Mil.
Revenue was 4.795 + 5.127 + 4.887 + 5.087 = $19.90 Mil.
Gross Profit was 4.795 + 5.127 + 4.887 + 5.087 = $19.90 Mil.
Total Current Assets was $541.60 Mil.
Total Assets was $635.68 Mil.
Property, Plant and Equipment(Net PPE) was $42.47 Mil.
Depreciation, Depletion and Amortization(DDA) was $7.66 Mil.
Selling, General, & Admin. Expense(SGA) was $66.29 Mil.
Total Current Liabilities was $43.02 Mil.
Long-Term Debt & Capital Lease Obligation was $0.00 Mil.




1. DSRI = Days Sales in Receivables Index

Measured as the ratio of Revenue in Total Receivables in year t to year t-1.

A large increase in DSR could be indicative of revenue inflation.

DSRI=(Receivables_t / Revenue_t) / (Receivables_t-1 / Revenue_t-1)
=(0 / 32.136) / (0 / 19.896)
=0 / 0
=1

2. GMI = Gross Margin Index

Measured as the ratio of gross margin in year t-1 to gross margin in year t.

Gross margin has deteriorated when this index is above 1. A firm with poorer prospects is more likely to manipulate earnings.

GMI=GrossMargin_t-1 / GrossMargin_t
=(GrossProfit_t-1 / Revenue_t-1) / (GrossProfit_t / Revenue_t)
=(19.896 / 19.896) / (32.136 / 32.136)
=1 / 1
=1

3. AQI = Asset Quality Index

AQI is the ratio of asset quality in year t to year t-1.

Asset quality is measured as the ratio of non-current assets other than Property, Plant and Equipment to Total Assets.

AQI=(1 - (CurrentAssets_t + PPE_t) / TotalAssets_t) / (1 - (CurrentAssets_t-1 + PPE_t-1) / TotalAssets_t-1)
=(1 - (798.28 + 49.722) / 907.113) / (1 - (541.598 + 42.466) / 635.675)
=0.065164 / 0.081191
=0.8026

4. SGI = Sales Growth Index

Ratio of Revenue in year t to sales in year t-1.

Sales growth is not itself a measure of manipulation. However, growth companies are likely to find themselves under pressure to manipulate in order to keep up appearances.

SGI=Sales_t / Sales_t-1
=Revenue_t / Revenue_t-1
=32.136 / 19.896
=1.6152

5. DEPI = Depreciation Index

Measured as the ratio of the rate of Depreciation, Depletion and Amortization in year t-1 to the corresponding rate in year t.

DEPI greater than 1 indicates that assets are being depreciated at a slower rate. This suggests that the firm might be revising useful asset life assumptions upwards, or adopting a new method that is income friendly.

DEPI=(Depreciation_t-1 / (Depreciaton_t-1 + PPE_t-1)) / (Depreciation_t / (Depreciaton_t + PPE_t))
=(7.662 / (7.662 + 42.466)) / (12.687 / (12.687 + 49.722))
=0.152849 / 0.203288
=0.7519

Note: If the Depreciation, Depletion and Amortization data is not available, we assume that the depreciation rate is constant and set the Depreciation Index to 1.

6. SGAI = Sales, General and Administrative expenses Index

The ratio of Selling, General, & Admin. Expense(SGA) to Sales in year t relative to year t-1.

SGA expenses index > 1 means that the company is becoming less efficient in generate sales.

SGAI=(SGA_t / Sales_t) / (SGA_t-1 /Sales_t-1)
=(134.352 / 32.136) / (66.29 / 19.896)
=4.180732 / 3.331825
=1.2548

7. LVGI = Leverage Index

The ratio of total debt to Total Assets in year t relative to yeat t-1.

An LVGI > 1 indicates an increase in leverage

LVGI=((LTD_t + CurrentLiabilities_t) / TotalAssets_t) / ((LTD_t-1 + CurrentLiabilities_t-1) / TotalAssets_t-1)
=((0 + 88.564) / 907.113) / ((0 + 43.019) / 635.675)
=0.097633 / 0.067675
=1.4427

8. TATA = Total Accruals to Total Assets

Total accruals calculated as the change in working capital accounts other than cash less depreciation.

TATA=(IncomefromContinuingOperations_t - CashFlowsfromOperations_t) / TotalAssets_t
=(NetIncome_t - NonOperatingIncome_t - CashFlowsfromOperations_t) / TotalAssets_t
=(-359.102 - -2.807 - -155.805) / 907.113
=-0.22102

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator. An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Kite Pharma has a M-score of -3.26 suggests that the company is unlikely to be a manipulator.


Kite Pharma Beneish M-Score Related Terms

Thank you for viewing the detailed overview of Kite Pharma's Beneish M-Score provided by GuruFocus.com. Please click on the following links to see related term pages.


Kite Pharma (Kite Pharma) Business Description

Traded in Other Exchanges
N/A
Address
Kite Pharma is a clinical-stage biopharmaceutical company engaged in the development of novel cancer immunotherapy products. In partnership with the National Cancer Institute through a cooperative research and development agreement, Kite is advancing a pipeline of proprietary product candidates, both chimeric antigen receptor and T-cell receptor products, targeting a wide range of cancer indications. The company also has a strategic collaboration with Amgen to develop and commercialize next-generation CAR-T therapies.
Executives
Jonathan M Peacock director ONE AMGEN CENTER DRIVE, THOUSAND OAKS CA 91320-1799
David Bonderman director 301 COMMERCE STREET, SUITE 3300, FORT WORTH TX 76102
Franz B Humer director 388 GREENWICH STREET, 17TH FLOOR, NEW YORK NY 10013
Shawn Tomasello officer: Chief Commercial Officer C/O PHARMACYCLICS, INC, 995 EAST ARQUES AVENUE, SUNNYVALE CA 94085
Ian T Clark director SOLAZYME, INC., 225 GATEWAY BLVD., SOUTH SAN FRANCISCO CA 94080
Farah Champsi director ONE EMBARCADERO CENTER SUITE 3700, SAN FRANCISCO CA 94111
Helen Susan Kim officer: EVP, Business Development 3832 BAY CENTER PLACE, HAYWARD CA 94545
Timothy L. Moore officer: EVP, Technical Operations C/O KITE PHARMA, INC., 2225 COLORADO AVE., SANTA MONICA CA 90404
Ran Nussbaum director C/O KITE PHARMA, INC., 2225 COLORADO AVENUE, SANTA MONICA CA 90404
Cynthia M Butitta officer: Chief Operating Officer 3165 PORTER DRIVE, PALO ALTO CA 94304
Owen N. Witte director C/O ALLOGENE THERAPEUTICS, INC., 210 EAST GRAND AVENUE, SOUTH SAN FRANCISCO CA 94080
David D Chang officer: EVP, R&D, Chief Medical Off. C/O ALLOGENE THERAPEUTICS, INC., 210 EAST GRAND AVENUE, SOUTH SAN FRANCISCO CA 94080
Joshua A Kazam director 689 5TH AVENUE, 12TH FLOOR, NEW YORK NY 10022
Arie Belldegrun director, officer: Chairman, President and CEO UCLA SCHOOL OF MEDICINE, 10833 LE CONTE 66-118 CHS BOX 951738, LOS ANGELES CA 9095-1738
Margo R Roberts officer: Chief Scientific Officer 2225 COLORADO AVENUE, SANTA MONICA CA 90404

Kite Pharma (Kite Pharma) Headlines

From GuruFocus

Andreas Halvorsen Nearly Quadruples Stake in Kite Pharma

By David Goodloe David Goodloe 10-06-2015

Multiple Companies Achieve Yearly Highs

By yifan900 yifan900 10-03-2017

Mario Gabelli Exits Kite Pharma, Trims Time Warner

By Tiziano Frateschi Tiziano Frateschi 02-07-2018

Mario Gabelli's Top 5 New Buys for the 3rd Quarter

By Sydnee Gatewood Sydnee Gatewood 11-03-2017